Low‐molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
BACKGROUND. The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays. In the current study, they analyzed the expression of low‐molecular weight (LMW) forms of cyclin E in ovarian...
Gespeichert in:
| Veröffentlicht in: | Cancer 2007-09, Vol.110 (6), p.1264-1271 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1271 |
|---|---|
| container_issue | 6 |
| container_start_page | 1264 |
| container_title | Cancer |
| container_volume | 110 |
| creator | Davidson, Ben Skrede, Martina Silins, Ilvars Shih, Ie‐Ming Trope, Claes G. Flørenes, Vivi Ann |
| description | BACKGROUND.
The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays. In the current study, they analyzed the expression of low‐molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions.
METHODS.
Cyclin E protein expression was analyzed in 98 effusions (72 ovarian carcinomas, 14 malignant mesotheliomas, and 12 reactive specimens) using immunoblotting. Sixty‐two ovarian carcinoma effusions were studied further for cyclin E expression using immunohistochemistry. The correlations between cyclin E expression in ovarian carcinoma and clinical parameters, including chemotherapy response, were analyzed.
RESULTS.
LMW forms of cyclin E were identified in 54 of 72 ovarian carcinoma effusions (75%) compared with 1 of 14 malignant mesothelioma effusions (7%) and 1 of 12 reactive effusions (8%) (P < .001). Their presence in ovarian carcinoma was associated with a higher percentage of cyclin E‐positive cells (P = .001) and increased staining intensity (P < .001) using immunohistochemistry. The presence of LMW forms of cyclin E was correlated with shorter overall survival (P = .021) and progression‐free survival (P = .020). The presence of a higher percentage of cyclin E‐positive cells using immunohistochemistry was correlated with shorter progression‐free survival (P = .026). No association with chemotherapy response was observed.
CONCLUSIONS.
LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry. The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma. Cancer 2007. © 2007 American Cancer Society.
Expression of the low‐molecular weight (LMW) forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and was associated with increased cyclin E protein expression in immunohistochemical analyses. LMW cyclin E expression was unrelated chemotherapy response; however, the current results indicated that these LMW forms may be markers of aggressive disease in patients with metastatic ovarian carcinoma. |
| doi_str_mv | 10.1002/cncr.22918 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68251005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68251005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3938-5565642b4e41a27fc22ef274c4204bb41819eb83d983405e2c10b76f9cb8a91a3</originalsourceid><addsrcrecordid>eNp9kc1q3DAURkVpaaZJN32AoE2zKEwqybItL8OQPxhaCC1kZ67lq4yCbE0ke4bZ9RH6EH2yPEnlzEAWha4uF47Ox9VHyCfOzjlj4qvudTgXouLqDZlxVpVzxqV4S2aMMTXPZXZ_RD7E-JjWUuTZe3LEy0KWomAz8mfpt8-_fnfeoR4dBLpF-7AaqPGhi9Qbqnfa2Z5e0tYagwH7wcKA1G8gWOiphqBt7zugJviOanTu5VmH0Q8rdBYc9cE-JAX0LYWAFGL0epK0dGuHFV17H2gcw8ZuEpzAf9wn5J0BF_HjYR6Tn1eXPxY38-X369vFxXKusypLl-ZFXkjRSJQcRGm0EGhEKbUUTDaN5IpX2KisrVQmWY5Cc9aUhal0o6DikB2Ts713HfzTiHGoOxunk6BHP8a6UCJPP54n8Mse1MHHGNDU62A7CLuas3rqpJ46qV86SfDpwTo2Hbav6KGEBHw-ABA1OBOg1za-chWTuVJTKt9zW-tw95_IevFtcbcP_wtOH6gq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68251005</pqid></control><display><type>article</type><title>Low‐molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Davidson, Ben ; Skrede, Martina ; Silins, Ilvars ; Shih, Ie‐Ming ; Trope, Claes G. ; Flørenes, Vivi Ann</creator><creatorcontrib>Davidson, Ben ; Skrede, Martina ; Silins, Ilvars ; Shih, Ie‐Ming ; Trope, Claes G. ; Flørenes, Vivi Ann</creatorcontrib><description>BACKGROUND.
The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays. In the current study, they analyzed the expression of low‐molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions.
METHODS.
Cyclin E protein expression was analyzed in 98 effusions (72 ovarian carcinomas, 14 malignant mesotheliomas, and 12 reactive specimens) using immunoblotting. Sixty‐two ovarian carcinoma effusions were studied further for cyclin E expression using immunohistochemistry. The correlations between cyclin E expression in ovarian carcinoma and clinical parameters, including chemotherapy response, were analyzed.
RESULTS.
LMW forms of cyclin E were identified in 54 of 72 ovarian carcinoma effusions (75%) compared with 1 of 14 malignant mesothelioma effusions (7%) and 1 of 12 reactive effusions (8%) (P < .001). Their presence in ovarian carcinoma was associated with a higher percentage of cyclin E‐positive cells (P = .001) and increased staining intensity (P < .001) using immunohistochemistry. The presence of LMW forms of cyclin E was correlated with shorter overall survival (P = .021) and progression‐free survival (P = .020). The presence of a higher percentage of cyclin E‐positive cells using immunohistochemistry was correlated with shorter progression‐free survival (P = .026). No association with chemotherapy response was observed.
CONCLUSIONS.
LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry. The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma. Cancer 2007. © 2007 American Cancer Society.
Expression of the low‐molecular weight (LMW) forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and was associated with increased cyclin E protein expression in immunohistochemical analyses. LMW cyclin E expression was unrelated chemotherapy response; however, the current results indicated that these LMW forms may be markers of aggressive disease in patients with metastatic ovarian carcinoma.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.22918</identifier><identifier>PMID: 17647260</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Carcinoma - chemistry ; Carcinoma - mortality ; chemotherapy ; cyclin E ; Cyclin E - analysis ; Disease-Free Survival ; effusions ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Immunoblotting ; Immunohistochemistry ; malignant mesothelioma ; Medical sciences ; Mesothelioma - chemistry ; Mesothelioma - mortality ; Middle Aged ; Molecular Weight ; ovarian carcinoma ; Ovarian Neoplasms - chemistry ; Ovarian Neoplasms - mortality ; survival ; Survival Analysis ; Tumors</subject><ispartof>Cancer, 2007-09, Vol.110 (6), p.1264-1271</ispartof><rights>Copyright © 2007 American Cancer Society</rights><rights>2007 INIST-CNRS</rights><rights>(c) 2007 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3938-5565642b4e41a27fc22ef274c4204bb41819eb83d983405e2c10b76f9cb8a91a3</citedby><cites>FETCH-LOGICAL-c3938-5565642b4e41a27fc22ef274c4204bb41819eb83d983405e2c10b76f9cb8a91a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.22918$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.22918$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19045885$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17647260$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Davidson, Ben</creatorcontrib><creatorcontrib>Skrede, Martina</creatorcontrib><creatorcontrib>Silins, Ilvars</creatorcontrib><creatorcontrib>Shih, Ie‐Ming</creatorcontrib><creatorcontrib>Trope, Claes G.</creatorcontrib><creatorcontrib>Flørenes, Vivi Ann</creatorcontrib><title>Low‐molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND.
The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays. In the current study, they analyzed the expression of low‐molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions.
METHODS.
Cyclin E protein expression was analyzed in 98 effusions (72 ovarian carcinomas, 14 malignant mesotheliomas, and 12 reactive specimens) using immunoblotting. Sixty‐two ovarian carcinoma effusions were studied further for cyclin E expression using immunohistochemistry. The correlations between cyclin E expression in ovarian carcinoma and clinical parameters, including chemotherapy response, were analyzed.
RESULTS.
LMW forms of cyclin E were identified in 54 of 72 ovarian carcinoma effusions (75%) compared with 1 of 14 malignant mesothelioma effusions (7%) and 1 of 12 reactive effusions (8%) (P < .001). Their presence in ovarian carcinoma was associated with a higher percentage of cyclin E‐positive cells (P = .001) and increased staining intensity (P < .001) using immunohistochemistry. The presence of LMW forms of cyclin E was correlated with shorter overall survival (P = .021) and progression‐free survival (P = .020). The presence of a higher percentage of cyclin E‐positive cells using immunohistochemistry was correlated with shorter progression‐free survival (P = .026). No association with chemotherapy response was observed.
CONCLUSIONS.
LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry. The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma. Cancer 2007. © 2007 American Cancer Society.
Expression of the low‐molecular weight (LMW) forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and was associated with increased cyclin E protein expression in immunohistochemical analyses. LMW cyclin E expression was unrelated chemotherapy response; however, the current results indicated that these LMW forms may be markers of aggressive disease in patients with metastatic ovarian carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Carcinoma - chemistry</subject><subject>Carcinoma - mortality</subject><subject>chemotherapy</subject><subject>cyclin E</subject><subject>Cyclin E - analysis</subject><subject>Disease-Free Survival</subject><subject>effusions</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunoblotting</subject><subject>Immunohistochemistry</subject><subject>malignant mesothelioma</subject><subject>Medical sciences</subject><subject>Mesothelioma - chemistry</subject><subject>Mesothelioma - mortality</subject><subject>Middle Aged</subject><subject>Molecular Weight</subject><subject>ovarian carcinoma</subject><subject>Ovarian Neoplasms - chemistry</subject><subject>Ovarian Neoplasms - mortality</subject><subject>survival</subject><subject>Survival Analysis</subject><subject>Tumors</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1q3DAURkVpaaZJN32AoE2zKEwqybItL8OQPxhaCC1kZ67lq4yCbE0ke4bZ9RH6EH2yPEnlzEAWha4uF47Ox9VHyCfOzjlj4qvudTgXouLqDZlxVpVzxqV4S2aMMTXPZXZ_RD7E-JjWUuTZe3LEy0KWomAz8mfpt8-_fnfeoR4dBLpF-7AaqPGhi9Qbqnfa2Z5e0tYagwH7wcKA1G8gWOiphqBt7zugJviOanTu5VmH0Q8rdBYc9cE-JAX0LYWAFGL0epK0dGuHFV17H2gcw8ZuEpzAf9wn5J0BF_HjYR6Tn1eXPxY38-X369vFxXKusypLl-ZFXkjRSJQcRGm0EGhEKbUUTDaN5IpX2KisrVQmWY5Cc9aUhal0o6DikB2Ts713HfzTiHGoOxunk6BHP8a6UCJPP54n8Mse1MHHGNDU62A7CLuas3rqpJ46qV86SfDpwTo2Hbav6KGEBHw-ABA1OBOg1za-chWTuVJTKt9zW-tw95_IevFtcbcP_wtOH6gq</recordid><startdate>20070915</startdate><enddate>20070915</enddate><creator>Davidson, Ben</creator><creator>Skrede, Martina</creator><creator>Silins, Ilvars</creator><creator>Shih, Ie‐Ming</creator><creator>Trope, Claes G.</creator><creator>Flørenes, Vivi Ann</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070915</creationdate><title>Low‐molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma</title><author>Davidson, Ben ; Skrede, Martina ; Silins, Ilvars ; Shih, Ie‐Ming ; Trope, Claes G. ; Flørenes, Vivi Ann</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3938-5565642b4e41a27fc22ef274c4204bb41819eb83d983405e2c10b76f9cb8a91a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Carcinoma - chemistry</topic><topic>Carcinoma - mortality</topic><topic>chemotherapy</topic><topic>cyclin E</topic><topic>Cyclin E - analysis</topic><topic>Disease-Free Survival</topic><topic>effusions</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunoblotting</topic><topic>Immunohistochemistry</topic><topic>malignant mesothelioma</topic><topic>Medical sciences</topic><topic>Mesothelioma - chemistry</topic><topic>Mesothelioma - mortality</topic><topic>Middle Aged</topic><topic>Molecular Weight</topic><topic>ovarian carcinoma</topic><topic>Ovarian Neoplasms - chemistry</topic><topic>Ovarian Neoplasms - mortality</topic><topic>survival</topic><topic>Survival Analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Davidson, Ben</creatorcontrib><creatorcontrib>Skrede, Martina</creatorcontrib><creatorcontrib>Silins, Ilvars</creatorcontrib><creatorcontrib>Shih, Ie‐Ming</creatorcontrib><creatorcontrib>Trope, Claes G.</creatorcontrib><creatorcontrib>Flørenes, Vivi Ann</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Davidson, Ben</au><au>Skrede, Martina</au><au>Silins, Ilvars</au><au>Shih, Ie‐Ming</au><au>Trope, Claes G.</au><au>Flørenes, Vivi Ann</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low‐molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2007-09-15</date><risdate>2007</risdate><volume>110</volume><issue>6</issue><spage>1264</spage><epage>1271</epage><pages>1264-1271</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND.
The authors recently reported on the role of cyclin E in differentiating ovarian/primary peritoneal carcinoma from malignant peritoneal mesothelioma using gene expression arrays. In the current study, they analyzed the expression of low‐molecular weight (LMW) forms of cyclin E in ovarian carcinoma, malignant mesothelioma, and benign reactive effusions.
METHODS.
Cyclin E protein expression was analyzed in 98 effusions (72 ovarian carcinomas, 14 malignant mesotheliomas, and 12 reactive specimens) using immunoblotting. Sixty‐two ovarian carcinoma effusions were studied further for cyclin E expression using immunohistochemistry. The correlations between cyclin E expression in ovarian carcinoma and clinical parameters, including chemotherapy response, were analyzed.
RESULTS.
LMW forms of cyclin E were identified in 54 of 72 ovarian carcinoma effusions (75%) compared with 1 of 14 malignant mesothelioma effusions (7%) and 1 of 12 reactive effusions (8%) (P < .001). Their presence in ovarian carcinoma was associated with a higher percentage of cyclin E‐positive cells (P = .001) and increased staining intensity (P < .001) using immunohistochemistry. The presence of LMW forms of cyclin E was correlated with shorter overall survival (P = .021) and progression‐free survival (P = .020). The presence of a higher percentage of cyclin E‐positive cells using immunohistochemistry was correlated with shorter progression‐free survival (P = .026). No association with chemotherapy response was observed.
CONCLUSIONS.
LMW forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and were associated with increased protein expression using immunohistochemistry. The expression of LMW cyclin E forms was not associated with chemotherapy response, although it may be a marker of aggressive disease in patients with metastatic ovarian carcinoma. Cancer 2007. © 2007 American Cancer Society.
Expression of the low‐molecular weight (LMW) forms of cyclin E differentiated ovarian carcinoma from benign and malignant mesothelial cells and was associated with increased cyclin E protein expression in immunohistochemical analyses. LMW cyclin E expression was unrelated chemotherapy response; however, the current results indicated that these LMW forms may be markers of aggressive disease in patients with metastatic ovarian carcinoma.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>17647260</pmid><doi>10.1002/cncr.22918</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2007-09, Vol.110 (6), p.1264-1271 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68251005 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Biomarkers, Tumor - analysis Carcinoma - chemistry Carcinoma - mortality chemotherapy cyclin E Cyclin E - analysis Disease-Free Survival effusions Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Immunoblotting Immunohistochemistry malignant mesothelioma Medical sciences Mesothelioma - chemistry Mesothelioma - mortality Middle Aged Molecular Weight ovarian carcinoma Ovarian Neoplasms - chemistry Ovarian Neoplasms - mortality survival Survival Analysis Tumors |
| title | Low‐molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T14%3A22%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%E2%80%90molecular%20weight%20forms%20of%20cyclin%20E%20differentiate%20ovarian%20carcinoma%20from%20cells%20of%20mesothelial%20origin%20and%20are%20associated%20with%20poor%20survival%20in%20ovarian%20carcinoma&rft.jtitle=Cancer&rft.au=Davidson,%20Ben&rft.date=2007-09-15&rft.volume=110&rft.issue=6&rft.spage=1264&rft.epage=1271&rft.pages=1264-1271&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.22918&rft_dat=%3Cproquest_cross%3E68251005%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68251005&rft_id=info:pmid/17647260&rfr_iscdi=true |